Effect of Modified Simiaosan on Early Lesions of AS Rats

WANG Jin-biao; LUO Tian-jiong; CHENG Kun; JIANG Bao-ping

doi:10.13422/j.cnki.syfjx.2017020126

您当前的位置：

首页 >

文章列表页 >

Effect of Modified Simiaosan on Early Lesions of AS Rats

更新时间：2024-01-04

- Effect of Modified Simiaosan on Early Lesions of AS Rats
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 23, Issue 2, Pages: 126-130(2017)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.2017020126
  CLC： R285.5
- Published：2017
- 稿件说明：
移动端阅览
WANG Jin-biao, LUO Tian-jiong, CHENG Kun, et al. Effect of Modified Simiaosan on Early Lesions of AS Rats[J]. Chinese journal of experimental traditional medical formulae, 2017, 23(2): 126-130.
DOI：

WANG Jin-biao, LUO Tian-jiong, CHENG Kun, et al. Effect of Modified Simiaosan on Early Lesions of AS Rats[J]. Chinese journal of experimental traditional medical formulae, 2017, 23(2): 126-130. DOI： 10.13422/j.cnki.syfjx.2017020126.

摘要

目的：观察加减四妙散对动脉粥样硬化大鼠血脂、降钙素、抵抗素及主动脉弓部病理状态的影响。方法： SPF级SD大鼠60只雌雄各半，随机分为6组，分别为正常组，阳性药组（阿托伐他汀，0.83 mg·kg-1），模型组，加减四妙散低、中、高剂量组（0.325，0.650，1.300 g·kg-1）。除正常组外，余以18%猪油，7%胆固醇，1%牛胆盐与花生油配成糊状乳糜液，按照10 mL·kg-1每天ig 1次，连续8周造模，8周后给药，同时维持造模，给药6周后禁食12 h，处死取血液检测总胆固醇（TC），甘油三酯（TG），血糖（Glu），低密度脂蛋白胆固醇（LDL-C），高密度脂蛋白胆固醇（HDL-C），降钙素基因相关肽（CGRP）及抵抗素含量，计算大鼠肝脂数，Lees肝脂数及脂肪指数，取心脏及主动脉做病理切片，苏木素-伊红（HE）染色观察各组主动脉病理状况。结果：与正常组比较，模型组大鼠血清中TC，TG，Glu，LDL-C及抵抗素含量均升高，肝指数，Lees指数及脂肪指数均明显增加，HDL-C，CGRP含量明显降低（P < 0.05，P < 0.01），同时病理显示高脂模型大鼠出现主动脉硬化早期病变，证明实验成功复制了动脉粥样硬化早期模型；与模型组比较，阿托伐他汀组、加减四妙散高组明显降低TC，TG，Glu，LDL-C及抵抗素含量，加减四妙散中、高组明显降低肝指数，Lees指数及脂肪指数（P < 0.05，P < 0.01），加减四妙散中、高组明显升高HDL-C，CGRP含量（P < 0.05，P < 0.01），病理提示其病理发展较模型组有改善。结论：四妙散颗粒可以降低血脂，降低低密度脂蛋白，并通过调节炎症因子来改善动脉粥样硬化，减缓其发展，对动脉粥样硬化预防与治疗有积极作用。

Abstract

Objective: To observe the effects of modified Simiaosan on lipids

calcitonin

rsistin and pathological state of aortic arch of atherosclerosis rats. Method: Totally 60 male and female SPF-grade rats were randomly divided into 6 groups:blank group

positive group (atorvastatin

0.83 mg·kg-1)

model group

low dose

middle dose and high dose modified Simiaosan groups (0.325

0.650

1.300 g·kg-1). Except for the blank group

other groups were fed with 10 mL·kg-1 mash (18% lard

7% cholesterol

1% bovine bile salt

74% peanut oil) once a day. After eight weeks of modeling

the rats were given drugs. After six weeks

the rats were fasted for 12 h before killed to detect blood content of total cholesterol (TC)

triglyceride (TG)

glucose

low density lipoprotein cholesterin (LDL-C)

high density lipoprotein cholesterol (HDL-C)

calcitonin generelated peptide (CGRP) and resistin

and calculate rat liver index

Lee's liver index and fat index. Their heart and aorta were collected to make pathological sections. HE staining was performed to observe aortic pathological conditions of each group. Result: Compared with the blank control group

the levels of serum TC

Glu

LDL-C and resistin content in the model group were elevated (P < 0.05

P < 0.01)

rat liver index

Lee's liver index and fat index were significantly increased

and HDL-C and CGRP content were elevated (P < 0.05

P < 0.01). At the same time

pathology results showed early lesions of aortic atherosclerosis among hyperlipidemia rats. This proves that the experiment successfully replicated the early atherosclerosis model. Compared with the model group

the positive group and the modified Simiaosan high-dose group showed notable reduction in TC

Glu

LDL-C and resistin content

modified Simiaosan medium and high-dose groups showed notable reduction in rat liver index

Lee's liver index and fat index (P < 0.05

P < 0.01) and remarkable increase in HDL-C and CGRP content (P < 0.05

P < 0.01). The pathological results also showed alleviation in pathological process compared with the model group. Conclusion: Modified Simiaosan may reduce cholesterol

LDL and alliviate atherosclerosis by regulating inflammatory cytokines

with a good effect in atherosclerosis prevention and treatment.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Exploration of Zhuyuwan in Treatment of Atherosclerosis from Perspective of Lipid Transport Disorder

Mechanism of Huangqi Chifengtang in Treating Atherosclerosis Based on 16S rRNA Sequencing and Metabolomics

Effect of Co-treatment Method of Stagnation of Phlegm and Blood Stasis （Danlou Tablet） on Vascular Endothelial Function in Patients with Atherosclerosis

Molecular Mechanism of Treating Different Diseases with Same Treatment of Gypenoside L Affecting Oxidative Damage HUVEC and OVCAR-3 Through EGFR/STAT3/Glycolytic Pathway

Analysis of Mechanism of Astragaloside Ⅳ in Regulating Ferroptosis Through SLC7A11/GPX4 Pathway Against Vascular Smooth Muscle Cell Proliferation

Related Author

SONG Wei

ZHANG Zhongyi

QIU Hairong

ZHAO Mei

ZHOU Zubing

SHEN Tao

ZHANG Yong

LIANG Yuqin

Related Institution

Chengdu University of Traditional Chinese Medicine（TCM）

Hospital of Chengdu University of TCM

Hubei Minzu University

Institute of TCM， Sichuan Academy of Chinese Medicine Sciences

Institute of Traditional Chinese Medicine， Heilongjiang University of Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰